Search

everythinglearnresearchcommunity

for

Search:↓

Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.

A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.

New treatments for lupus show promise, but more research is needed, especially for children.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Hair dye may trigger anti-GBM disease relapse, and rituximab can help manage it.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.

Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.

Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.

Brodalumab is more effective than ustekinumab for treating psoriasis.

Adalimumab improved folliculitis decalvans in most patients.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.

Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.

Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.

Anti-CD19 therapy may help treat SLE and NMOSD.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.

Clofazimine effectively treated ashy dermatosis in a patient.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Infliximab may cause hair loss in Crohn's disease patients.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.